What high-risk features for stage I NSCLC would lead you to consider adjuvant osimertinib?
Would visceral pleural invasion lead you to consider adjuvant osimertinib?
Community PollStarted
What high-risk features for stage I NSCLC would lead you to consider adjuvant osimertinib?
71 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Answered on
In patients with resected stage IB non-small cell lung cancer (NSCLC) harboring EGFR mutations, adjuvant osimertinib may be considered for care. There is some evolving data that there may be some benefit in the presence of other risk factors in stage I, including solid or micropapillary histologic c...
Join for free or sign in to see the full answer